Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
NCT06572618Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nemtabrutinib in mantle cell lymphoma (MCL), sponsored by City of Hope. Started Jan 2025; status: recruiting.
02
Drugs
nemtabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06572618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572618.